Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?

Ferdinando D’Amico, Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese

Open source

DOI
10.1080/14712598.2020.1817374
Published
2020-09-06
Container
Expert Opinion on Biological Therapy
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14712598.2020.1817374,
  title = {Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?},
  author = {Ferdinando D’Amico and Virginia Solitano and Laurent Peyrin-Biroulet and Silvio Danese},
  year = {2020},
  journal = {Expert Opinion on Biological Therapy},
  doi = {10.1080/14712598.2020.1817374},
  url = {https://doi.org/10.1080/14712598.2020.1817374}
}

RIS

TY  - JOUR
TI  - Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?
AU  - Ferdinando D’Amico
AU  - Virginia Solitano
AU  - Laurent Peyrin-Biroulet
AU  - Silvio Danese
PY  - 2020
JO  - Expert Opinion on Biological Therapy
DO  - 10.1080/14712598.2020.1817374
UR  - https://doi.org/10.1080/14712598.2020.1817374
ER  - 

APA

D’Amico, F., Solitano, V., Peyrin-Biroulet, L., & Danese, S. (2020). Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1817374

Source records